ARGX - Argenx Vyvgart injectable granted EU nod for myasthenia gravis
2023-11-16 08:04:42 ET
More on Argenx SE
- argenx SE (ARGX) Q3 2023 Earnings Call Transcript
- argenx: Efgartigimod Is Not Just A Drug, A Cornerstone
- Argenx SE GAAP EPS of -$1.25 beats by $0.18, total operating income of $339.84M beats by $38.12M
- Immunovant drives OmniAb higher after data update; argenx slips
- Seeking Alpha’s Quant Rating on Argenx SE
For further details see:
Argenx Vyvgart injectable granted EU nod for myasthenia gravis